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Welcome… 
 
This is the first edition of Research Matters, a quarterly e-newsletter brought to you 
by the Center for Research & Grants. For those who are not aware of the resources the 
Center provides to the Baptist Health South Florida community, we have included a list 
of our services on the last page of this newsletter. Research Matters is intended to be 
an educational tool to: A) Provide information about industry trends, standards and 
guidelines that could impact how we conduct research at Baptist Health South Florida 
(BHSF), B) Disseminate information about BHSF research initiatives and policies 
throughout the system, and C) Inform researchers, and those who want to do research, 
about the resources BHSF has available. Each edition will provide regular features 
covering Industry News Updates, Research Compliance, Grants Updates, Library 
Services, a quarterly Education Calendar and more.  We welcome volunteer guest 
columnists as well as suggestions for research topics that you would like to hear about.  
For example, if you would like to write an editorial about the Sunshine Act and 
how it might impact doing research at BHSF, we would like to hear from 
you.  Please send Debbie Eyerdam (deborahey@baptisthealth.net) or Jossy 
Sanchez (josefinasa@baptisthealth.net) your questions, comments and 
suggestions.  We look forward to working together on Research 
Matters.  
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S P R I N G  2 0 1 2  E d i t i o n  V o l u m e  1 ,  I s s u e  1  
Looking for literature to 
support your research 
project?   Any Baptist Health 
staff member may use library 
resources for the 
improvement of quality of 
care of patients. Library 
services support  patient care, 
evidence based practice, 
continuing education, 
research and publications, 
and management.  Services 
include: computerized 
literature searches on 
MEDLINE, CINAHL  and 
other evidence-based health 
and business databases; 
document delivery to users 
electronically by e-mail, fax, 
photocopy or mail ; access to 
core reference and journal 
collection; circulation and 
interlibrary loan of 
books,  and DVDS for 
ongoing learning; electronic 
access to OVID MEDLINE 
and other databases and 
L i b r a r y  S e r v i c e s  
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Cont’d Library Services... 
e-textbooks and e-journals (from 
offices and  home, after library 
hours, using the ATHENS portal); 
and educating library users 
regarding effective searching for 
evidence based resources,  relative 
to the provision of excellent 
health care to patients. 
Wish you had access to funding to help support your program or research 
project but don’t know where to turn to for help?  Look no further, Baptist 
Health has a team of dedicated professionals to help you apply for grant 
funding.  The Grants Team is here for you and will help you every step of the 
way in the pre- and post-award process.  Serving the Baptist Health system 
and its employees, our subject matter experts have the experience to assist 
you in developing your research or program initiative, look for appropriate 
federal, state, local or foundation funding, guide you through the application 
process, compose and edit your proposal, build your budget, create an 
advisory board and timeline for your project, assist you in managing the 
award once awarded and much more! 
To learn about our wrap-around services or if you are ready to make a 
difference at Baptist Health and take the lead on a research or program 
launch, please email us at grantsinfo@baptisthealth.net. 
T h e  G r a n t s  Te a m   
 
 
 
 
Allison Bivin 
 
 
 
 
David Puente 
 
 
 
 
 
Karen Holmes 
EDC and EMR leading to increased 
remote monitoring – are we ready?  
By Jacqueline Mejias, BS, LPN, CCRC, CCRP 
 
The use of Electronic Medical Records (EMR) by sites and 
Electronic Data Capture (EDC) by sponsors will inevitably 
lead to increased remote monitoring instead of, or in 
addition to, the traditional on site monitoring visits.  In 
August 2011 the FDA issued a guidance titled “Guidance for 
Industry Oversight of Clinical Trial Investigations- A Risk 
Based Approach to Monitoring” in which it details the 
different monitoring methods that can be used while 
maintaining human subject protection and quality of clinical 
trial data as a top priority. (Walker, 2011) 
The previous FDA guidance on monitoring issued January 
1988 stated “the most effective way to monitor a trial was to 
maintain personal contact between the monitor and the 
investigator throughout the clinical investigation.” (FDA, 
2011) The new guidance is in keeping with the technological 
advances and changes in communication.  Email, webcasts, 
and online training modules are commonplace and already a 
large part of sites communicating with sponsors.  Remote 
monitoring would be an extension of that communication. 
It has been my experience that currently sponsors utilize a 
combination of on site and remote monitoring depending on 
complexity of clinical trial, data analysis deadlines, staff 
knowledge and experience.  The first visit is usually done in 
person and if the monitor feels the site knows what they are 
doing then subsequent visits may be done remotely. 
Changes in staff, protocol amendments, or lack of 
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enrollment may require on site visits. 
 The staff site will need to keep in mind the potential cost of 
remote monitoring.  The initial study agreement needs to 
clearly define what will be expected of monitors, coordinators 
and the Principal Investigator (PI) to make sure budget reflects 
the hours allocated for monitoring or a mechanism for 
invoicing. It is not uncommon for a coordinator to dedicate 
extensive hours completing EDC forms and then be asked for 
additional information via phone, email or data queries within 
EDC system as preparation for a monitoring visit - remote or 
on site. 
The guidance documents issued by the FDA are the current 
thinking on the topic and provide suggestions or 
recommendations but not legally enforceable responsibilities or  
requirements.   
It is clear that “no single approach to monitoring is appropriate or 
necessary for every clinical trial.” (FDA, 2011)  It is important to 
keep in mind that changes in technology will have an impact on 
clinical trials overall not just with monitoring. At the site level, 
being open to interactions whether it is via email, online chat, 
phone or in person will allow for a successful trial. 
Bibliography 
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Is Social Networking a Medical Breakthrough or a Media Disaster? 
By Ivette De Pool, B.A.  
Having jumped from 50 million users in 2007 to 800 million 
in 2011, Facebook™  is now the largest social networking site 
in the world, according to company figures.  With a quick 
click of the mouse and its vast array of services, users are able 
to connect within seconds. Facebook™  has the ability to keep 
users on its site for hours every day by providing features such 
as music streaming, advertising, delivery of the latest news 
and more. The evidence is clear, in less than a decade, this 
spaghetti digital connection has ballooned into a giant corpo-
rate social web, encouraging users to find new ways to com-
municate and share information. 
 
 Medical professionals are not exempt from using this technol-
ogy for the betterment or detriment of their careers.   Doc-
tors, nurses and researchers alike often consider social media 
as a way to exhibit their knowledge and educate those who are 
interested.  Therefore, social networking can be beneficial for 
patients. Networking allows patients to share personal experi-
ences and learn about treatment options based on similar ill-
nesses and experiences.  Also, networking can empower pa-
tients to take control of their health care decisions.  An in-
formed patient, leads to a rise in patient/provider relations, 
which in turn leads to healthier individuals overall.  “Fifty-
seven percent of Americans surf the web for health-related 
information”, reports The Pew Research Center in Washing-
ton, D.C. 
 
Moreover, pharmaceutical companies are also learning fairly 
quickly that networking has become a sure fire way to recruit 
participants for clinical trials.  Recruitment is one of the big-
gest obstacles that pharmaceutical companies face when initi-
ating a study.  The issue is that they are never able to reach 
certain demographics.  Social networking is able to open the 
door to specific groups and allow participant quotas to be met 
in a timely manner.  Scott Connor, VP of Marketing for Acu-
rian, a clinical trial patient recruitment and retention provider 
explains, “The Facebook™  ad network can display a clinical 
trial message to those Facebook™  users that you only want to 
target, say, women aged 40-54 for your female incontinent 
study and then you can narrow it further to only those women 
who live within 25 miles of your active clinical trial site.”   
 
The downside that stems from networking sites is that of pri-
vacy.  How much of it do we have, or not?  Keep in mind that 
once something is posted online, it never goes away.   Ryan 
Greysen, M.D., M. A, 
Clinical Scholar of the 
Robert Wood Johnson 
Foundation reiterates that, 
“physicians may not con-
sider the potential impact 
of their online content on 
their patients and the pub-
lic.  A momentary lapse in judgment by an individual physician 
to create unprofessional content online can reflect poorly on 
the entire profession.”  HIPAA Privacy Rule protects the pa-
tient’s health information, which is, “all individually identifi-
able health information held or transmitted by a covered en-
tity or its business associate, in any form or media, whether 
electronic, paper or oral.” 45C.F.R 160.103.   
 
Networking sites are designed for just that, to network.  
When using or posting something on a social networking site, 
take a moment and think.  Would this be considered a HIPAA 
violation?  Take precaution and be responsible for the use of 
social media because it can be a blessing if used properly, and 
a detriment if not. Remember, if you would not say it in an 
elevator, you certainly should not post it online. 
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What the Final Rule on FCOI in Research Means to BHSF investigators and Research Staff 
By Ofer Amit, MSEM, CHRC, Research Compliance Administrator  
The Department of Health and Human Services (HHS) has 
announced a Final Rule, that lays out Public Health Service 
(PHS) requirements relating to Individual Financial Conflict of 
Interest (FCOI) in research. Although the existing rule and the 
Final Rule are similar, the Final Rule includes new provisions 
and  changes to existing requirements. Among the changes,  
are a revised definition of the term Significant Financial Inter-
est (SFI), the addition of training requirements, expansion of 
the scope of required disclosures, and the inclusion of specific 
reporting and public disclosure requirements. Compliance 
with the Rule is required by August 24, 2012. 
 
Research institutions, sponsors, and governing bodies are 
aware of the ethical concerns that financial interests of investi-
gators and key research personnel can bring to bear. Most are 
cognizant of the effect conflicting financial interests for re-
searchers (whether real or perceived)  could have on the 
value, integrity and reputation of their research programs. To 
this end, the Food and Drug Administration (FDA) lays out its 
own criteria for the disclosure of financial interests of Clinical 
Investigators conducting a Covered Clinical Study. The Com-
mon Rule prohibits participation of Institutional Review Board 
(IRB) members in initial or continuing review of projects in 
which they have conflicting interests.  Similarly, the Final 
Rule, entitled “Promoting Objectivity in Research”, sets up 
the expectation that, following its implementation, “…the 
design, conduct, and reporting of research…will be free from 
bias resulting from Investigator financial conflicts of interest.” 
 
PHS is an office within the Department of Health and Human 
Services (HHS) that houses a number of HHS offices and agen-
cies including, for example, the National Institutes of Health 
(NIH), the Centers for Disease Control and Prevention 
(CDC) and the Food and Drug Administration (FDA). One of 
the key elements of the Final Rule, which applies to all PHS 
funding recipients, is the redefinition of the threshold for Sig-
nificant Financial Interest (SFI). The Final Rule distinguishes 
between financial interests in publicly traded entities and 
those in non-publicly traded entities.    It considers an amount 
in excess of $5,000 received from a publicly traded entity, 
when aggregated over the 12 month period preceding a disclo-
sure, for any remuneration for services and equity interests, 
an SFI.  Consider a scenario in which an investigator is holding 
shares of Boston Scientific - a public company that makes less-
invasive medical devices – and is speaking at a variety of com-
pany events. Over the 12 months prior to a disclosure, he or 
she received from Boston Scientific $3,000 in honoraria and 
$3,000 in dividends due to his or her holdings. In this case, 
the aggregate amount of his or her remunerations from Boston 
Scientific exceeds $5,000 thus constituting an SFI. 
 
The Final Rule is more stringent regarding equity interest 
(e.g., stock, stock option, or other ownership interest) in a 
non-publicly traded entity and deems any holding of such in-
terest SFI. For example, if an investigator is among a limited 
number of investors holding shares in a startup company, this 
holding, regardless of size, is considered SFI. Although not 
dubbed SFI, the Final Rule also requires disclosure of any re-
imbursed or sponsored travel. 
 
Additionally, the Final Rule mandates that Investigators com-
plete training on SFI. The Final Rule is not specific on the 
training’s content, delivery method or documentation. It 
places however the responsibility for obtaining such training 
with the investigator and requires completion prior to engag-
ing in research related to a PHS-funded award and at least 
every four years. 
 
Further, the Final Rule expands the investigator’s disclosure 
requirements. In doing so defines the term “investigator’s 
institutional responsibilities” as “Investigator's professional 
responsibilities on behalf of the Institution, and as defined by 
the Institution in its policy on financial conflicts of interest.” 
The Final Rule  thus means that everything and anything the 
investigator does as part of his or her relationship with the 
institution could, and probably should, be considered for dis-
closure purposes.  
 
The requirements for reporting and public disclosure  are ex-
panded as well. Prior to expenditure of PHS research funds, 
the institution must report to the funding agency any SFI of 
study’s Investigator(s) it found conflicting. Prior to spending 
PHS research funds and at any point thereafter, the institution 
must allow public access to study investigators’ SFI disclosures 
that 1) constitute FCOI, 2) are related to the specific study, 
and 3) pertain to interests held by the Investigator at the time 
of disclosure. 
.  
 
Continue … 
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addition to BHSF’s training on its 
policy. 
Make yourself available to training 
on BHSF policy on FCOI in research 
when it is offered. 
When requested to make an SFI 
disclosure to BHSF, do so promptly 
and fully. 
Work closely  with BHSF personnel 
responsible for receiving and vetting 
SFI disclosures. They can provide 
guidance  on this topic and help you 
throughout the process. 
If you need additional guidance, 
contact your research lead or 
Research Compliance 
ResearchCompliance@baptisthealth.net 
      786-594-6709. 
This article discusses only select provisions in 
42 CFR 50, Subpart F, Promoting Objectivity 
in Research and in 45 CFR 94, Responsible 
Prospective Contractors. The Center for 
Research and Grants (CR&G), in collaboration 
with additional BHSF resources, is currently 
updating BHSF policies in light of the Final 
Rule. As a BHSF Investigator or research team 
member, you can do the following: 
Inventory all financial relationships you 
have in connection with your 
responsibilities at BHSF. Include financial 
relationships that your family members 
have since, for Final Rule purposes, their 
financial interests may be considered 
yours. 
Inquire about training on SFI. BHSF 
provides training on its policy on FCOI in 
research. The training on SFI referenced in 
this piece is required separately and in 
C o n t ’ d … .  F i n a l  R u l e  o n  F C O I  i n  R e s e a r c h   
E d u c a t i o n a l  E v e n t s  
Announcements 
 
2nd Annual BHSF Research 
Pre-Conference: 
 
April 5, 2012 
BHM Auditorium 
Registration & Dinner:   
4-5pm 
Workshop:  5:00 – 8:00pm 
 
“Publishing in Scientific 
Journals”, a three hour work-
shop present by Thomas A. 
Lang, the former manager of 
medical editing services for 
Cleveland Clinic Foundation 
and author of How to Write, Pub-
lish, & Present in the Health Sci-
ences: A Guide For Clinicians & 
Laboratory Researchers 
 
 
7th Annual BHSF Research 
Conference 
 
April 6, 2012 
Kovens Conference Center 
(FIU North Campus) 
7:30am – 3:30pm 
 
“A Step Forward: Moving 
Research to the Bedside” by 
Keynote speaker,  Bradi 
Granger, RN, BSN, MSN, PhD 
  
 
First of a New Series   
“Investigator’s Exchange” 
 
May 23, 2012 
BHM Auditorium 
7:30 – 8:30am 
 
“Under-treatment of Os-
teoporosis and What Can 
Be Done about It” presented 
by Gary M. Kiebzak, PhD, 
Clinical Research Administra-
tor. This is the first of a series in 
which BHSF researchers will 
share their research findings 
with clinicians  for the purpose 
of improving patient care and 
implementing best practices. 
We invite BHSF Investigators 
from all disciplines to present 
and use this as a preparatory 
forum for speaking engage-
ments. 
Date & Time Event Location 
 Thursday, 3/8/12  
6:00 pm - 7:00 pm 
 Protocol Design: The 
Good , the  Bad and the 
Ugly 
BHM Auditorium 
 Friday, 3/9/12 
11:00 am - 12:30 pm 
STATISTICS: The Basics HH - Pineapple Room  
 Monday, 3/12/12 
12:00 pm - 1:30 pm  
Certification: Navigating 
the Application Process & 
Exam  
 BHM - Classroom 5 
Wednesday, 3/14/12 
8:00 am - 9:00 am 
WKBH Nursing & Allied 
Health Research Rounds 
WKBH - Classroom 4 & 5 
Friday, 3/16/12 
8:00 am - 9:00 am 
BHM Nursing & Allied 
Health Research Rounds 
BHM - Classroom 2 
Thursday, 4/19/12 
12:00 pm - 1:30 pm  
Learning to Communicate 
in Multidisciplinary Teams  
 BHM - Classroom 5 
Friday, 4/27/12 
7:30 am - 9:00 am 
Research Compliance: The 
Top 10 Things you Need to 
Know but are Afraid to Ask 
BHM - Classroom 5 
Tuesday, 5/15/12 
12:00 pm - 1:30 pm  
NTF vs. Correction Action 
Plan 
Town  & Country Corp 
Bldg - Conference Rm 2 
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Baptist Health South Florida 
Center for Research & Grants Fact Sheet 
Susan Golembeski, PhD; RN, CHRC - Assistant Vice President 
 
Research Administration: Jean McJilton (786) 594-6704 or ResearchAdmin@baptisthealth.net 
Research Administration assists with budget preparation and pricing, contract negotiation, Medicare Coverage Analysis, Humanitarian Use 
Devices (HUD/HDE) and any other research administrative issue.   
 
Clinical Trials Operations: Michelle Kirgan (786) 594-6701 or Mkirgan@baptisthealth.net 
Clinical Trials Operations provides employed physicians with clinical research assistance and coordinator support which includes but is not 
limited to protocol development, Institutional Review Board (IRB) submission, and regulatory guidance. Clinical Trials Operations also 
provides research support to Florida International University Medical Students. 
 
Nursing & Allied Health Research 
For more information on how to get started on a research project or learn more about research, evidence-based practice, the Institutional 
Review Board process, and statistics, please contact your Research Specialist. 
 
 
 
Research Fellowship Program: Tiffany Llera-Lora (786) 594-6714 or Tiffanyll@baptisthealth.net 
The (EBP) Fellowship Program guides our healthcare professionals to identify clinical problems and seek the best evidence to support 
changes in practice that can be facilitated by nursing and allied health.  This program is designed to assist these individuals in improving the 
quality of patient care they deliver through the learning and utilization of evidence-based principles at the bedside.   
 
Library Services: (786) 662.8219 or Library@baptisthhealth.net 
Any Baptist Health staff member may use library resources for the improvement of quality of care of patients. Library services support pa-
tient care, continuing education, research, publications and health care management.  
 
Grants Division: (786) 594-6701 or Grantsinfo@baptisthealth.net 
The Grants Division supports all aspects of the pre-award and post-award processes.  In the Pre-Award Process we will help you to navigate 
through the development of an application for government and research funding.  The Post-Award process focuses on contractual compli-
ance of your government and research award.  
 
Research Compliance: Ofer Amit (786) 594-6709 or Ofera@baptisthealth.net 
Research Compliance provides Baptist Health investigators and research teams with guidance, training, and oversight necessary to comply 
with international, federal and state regulations and Baptist Health policies that govern research.  
 
TCC Moffitt: Lisa C. Trebbi (786) 594-6705 or Lisat@baptisthealth.net 
Baptist Health has partnered with Tampa-based H. Lee Moffitt Cancer Center & Research Institute in a research study, called Total Cancer 
Care™ that may lead to individualized treatments for specific types of cancer.  Baptist Health joins the ranks of a select number of American 
healthcare institutions that have been chosen to participate in this landmark study.  Baptist Hospital, South Miami Hospital, and Doctors 
Hospital are the hospitals participating at this time.  
 
Outcomes Research: Don Parris (786)594-6715 or Donp@baptisthealth.net 
Investigators interested in conducting outcomes research can receive assistance in the areas of study design, research methodology, 
protocol development, manuscript writing, data management and statistical analysis.  
For more information visit us at http://intranet.bhssf.org/en/nursing/crg/Pages/default.aspx 
Baptist Hospital Eve Butler Eveb@baptisthealth.net 
Baptist Children’s Hospital Andrea Prentiss Andreap@baptisthealth.net 
Doctors Hospital Carolyn Lindgren Carolynl@baptisthealth.net 
Homestead & Mariners Hospital Maria Ojeda Mariaoj@baptisthealth.net 
South Miami Hospital Shakira Henderson Shakiralh@baptisthealth.net 
West Kendall Baptist Hospital Tanya Judkins-Cohn Tanyaco@baptisthealth.net 
